Related Experiment Video
Updated: Nov 10, 2025
07:40
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
4.4K
Current Knowledge about Providing Drug-Drug Interaction Services for Patients-A Scoping Review
Tora Hammar1, Sara Hamqvist2, My Zetterholm1,3
1Department of Medicine and Optometry, The eHealth Institute, Linnaeus University, 391 82 Kalmar, Sweden.
Pharmacy (Basel, Switzerland)
|April 3, 2021
Summary
Digital drug-drug interaction (DDI) services can aid patients, but quality varies significantly. Further research is needed to ensure safe and effective patient-facing DDI tools.
Area of Science:
- Health Informatics
- Patient Safety
- Digital Health
Background:
- Drug-drug interactions (DDIs) are a significant patient safety concern.
- eHealth solutions offer potential to improve medication management for professionals and patients.
- While clinical decision support systems (CDSS) for professionals are well-researched, patient-focused DDI support is less understood.
Purpose of the Study:
- To explore and describe the current knowledge on digital drug-drug interaction (DDI) services for patients.
- To identify existing DDI support services and understand patient demands and capabilities.
Main Methods:
- A scoping review was conducted using a broad search strategy.
- An established framework for scoping reviews was applied.
- Nineteen relevant papers were included in the analysis.
Main Results:
- Some patients desire to self-check for DDIs, with varying demands and abilities.
- Numerous digital DDI services exist, but quality variations pose potential safety risks.
- Suggestions for design features were identified, alongside a significant knowledge gap.
Conclusions:
- Patient-centered digital DDI services require careful design to ensure safety and avoid unintended consequences.
- Further research is essential to determine optimal methods for providing digital DDI support to patients.
- Addressing the variations in service quality is crucial for enhancing patient safety in digital health interventions.
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
94
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
94
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
54
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
54
01:15Drug Dosing: Geriatric Patients
76
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
76
01:14Agonism and Antagonism: Quantification
751
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
751
01:19Pharmacovigilance
1.4K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.4K
01:26Drug Administration and Therapy Phases: Overview
941
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
941